389 related articles for article (PubMed ID: 33508733)
1. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy.
Fucà G; Spagnoletti A; Ambrosini M; de Braud F; Di Nicola M
ESMO Open; 2021 Feb; 6(1):100046. PubMed ID: 33508733
[TBL] [Abstract][Full Text] [Related]
2. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Alcantara M; Du Rusquec P; Romano E
Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
[TBL] [Abstract][Full Text] [Related]
3. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.
Hovhannisyan L; Riether C; Aebersold DM; Medová M; Zimmer Y
Mol Cancer; 2023 May; 22(1):82. PubMed ID: 37173782
[TBL] [Abstract][Full Text] [Related]
4. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
5. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
Date V; Nair S
Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
[TBL] [Abstract][Full Text] [Related]
6. [Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors].
Ikeda H
Rinsho Ketsueki; 2019; 60(6):716-722. PubMed ID: 31281165
[TBL] [Abstract][Full Text] [Related]
7. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
8. CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.
Slaney CY; Wang P; Darcy PK; Kershaw MH
Cancer Discov; 2018 Aug; 8(8):924-934. PubMed ID: 30012854
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
11. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
12. Facing the future: challenges and opportunities in adoptive T cell therapy in cancer.
Magalhaes I; Carvalho-Queiroz C; Hartana CA; Kaiser A; Lukic A; Mints M; Nilsson O; Grönlund H; Mattsson J; Berglund S
Expert Opin Biol Ther; 2019 Aug; 19(8):811-827. PubMed ID: 30986360
[TBL] [Abstract][Full Text] [Related]
13. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
Guzman G; Reed MR; Bielamowicz K; Koss B; Rodriguez A
Curr Oncol Rep; 2023 May; 25(5):479-489. PubMed ID: 36853475
[TBL] [Abstract][Full Text] [Related]
14. Cell delivery devices for cancer immunotherapy.
Wen P; Wu W; Wang F; Zheng H; Liao Z; Shi J; Zhu C; Zhao P; Cheng H; Li H; Gu Z
J Control Release; 2023 Jan; 353():875-888. PubMed ID: 36442617
[TBL] [Abstract][Full Text] [Related]
15. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
16. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.
Jogalekar MP; Rajendran RL; Khan F; Dmello C; Gangadaran P; Ahn BC
Front Immunol; 2022; 13():925985. PubMed ID: 35936003
[TBL] [Abstract][Full Text] [Related]
17. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
18. RNA-electroporated T cells for cancer immunotherapy.
Pohl-Guimarães F; Hoang-Minh LB; Mitchell DA
Oncoimmunology; 2020 Oct; 9(1):1792625. PubMed ID: 33101771
[TBL] [Abstract][Full Text] [Related]
19. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.
Shin HG; Yang HR; Yoon A; Lee S
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
